CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
09. Januar 2025 09:12 ET
|
Rapport Therapeutics, Inc.
Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
09. Januar 2025 07:00 ET
|
Rapport Therapeutics, Inc.
Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.